Evidence map›Paper›PMID 35713905›Full record

ArticleJAMA network open2022

Epidemiological and Clinical Features of Kawasaki Disease During the COVID-19 Pandemic in the United States.

Jennifer A Burney, Samantha C Roberts, Laurel L DeHaan, Chisato Shimizu, Emelia V Bainto, Jane W Newburger, Samuel Dominguez, Pei-Ni Jone, Preeti Jaggi, Jacqueline R Szmuszkovicz and 7 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Kawasaki Disease in Canada: The Impact of the COVID-19 Pandemic.CJC pediatric and congenital heart disease · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. An Update on Kawasaki Disease.Current rheumatology reports · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. The etiologies of Kawasaki disease.The Journal of clinical investigation · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 1 country.

Jennifer A BurneySchool of Global Policy & Strategy, University of California, San Diego, La Jolla.
Samantha C RobertsDepartment of Pediatrics, University of California, San Diego, La Jolla.
Laurel L DeHaanScripps Institution of Oceanography, University of California, San Diego, La Jolla.
Chisato ShimizuDepartment of Pediatrics, University of California, San Diego, La Jolla.
Emelia V BaintoDepartment of Pediatrics, University of California, San Diego, La Jolla.
Jane W NewburgerDepartment of Cardiology, Boston Children's Hospital, Boston, Massachusetts.
Samuel DominguezDepartment of Pediatrics, Pediatric Cardiology, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora.
Pei-Ni JoneDepartment of Pediatrics, Pediatric Cardiology, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora.
Preeti JaggiChildren's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, Georgia.
Jacqueline R SzmuszkoviczDivision of Pediatric Cardiology, Children's Hospital Los Angeles, Keck School of Medicine of the University of Southern California, Los Angeles.
Anne H RowleyAnn & Robert H. Lurie Children's Hospital of Chicago, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Nichole SamuyUAB Heersink, School of Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham.
Paul ScaliciUAB Heersink, School of Medicine, Department of Pediatrics, University of Alabama at Birmingham, Birmingham.
Adriana H TremouletDepartment of Pediatrics, University of California, San Diego, La Jolla.
Daniel R CayanScripps Institution of Oceanography, University of California, San Diego, La Jolla.
Jane C BurnsDepartment of Pediatrics, University of California, San Diego, La Jolla.
KIDCARE Study Investigators
ThedaCare · USUniversity of California San Diego · USChildren's Hospital Colorado · USUniversity of Alabama at Birmingham · USBoston Children's Hospital · USNorthwestern University · USScripps Institution of Oceanography · USUniversity of Southern California · USEmory University · US

Funding

Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Hisashi Umemori · 2021 to 2026
$9.4M
NICHD NIH HHS P50 HD105351
6 · The paper itself

Abstract

Importance: Public health measures implemented during the COVID-19 pandemic had widespread effects on population behaviors, transmission of infectious diseases, and exposures to environmental pollutants. This provided an opportunity to study how these factors potentially influenced the incidence of Kawasaki disease (KD), a self-limited pediatric vasculitis of unknown etiology. Objectives: To examine the change in KD incidence across the United States and evaluate whether public health measures affected the prevalence of KD. Design, Setting, and Participants: This multicenter cohort study included consecutive, unselected patients with KD who were diagnosed between January 1, 2018, and December 31, 2020 (multicenter cohort with 28 pediatric centers), and a detailed analysis of patients with KD who were diagnosed between January 1, 2002, and November 15, 2021 (Rady Children's Hospital San Diego [RCHSD]). Main Outcomes and Measures: For the multicenter cohort, the date of fever onset for each patient with KD was collected. For RCHSD, detailed demographic and clinical data as well as publicly available, anonymized mobile phone data and median household income by census block group were collected. The study hypothesis was that public health measures undertaken during the pandemic would reduce exposure to the airborne trigger(s) of KD and that communities with high shelter-in-place compliance would experience the greatest decrease in KD incidence. Results: A total of 2461 KD cases were included in the multicenter study (2018: 894; 2019: 905; 2020: 646), and 1461 cases (median [IQR] age, 2.8 years [1.4-4.9 years]; 900 [61.6%] males; 220 [15.1%] Asian, 512 [35.0%] Hispanic, and 338 [23.1%] White children) from RCHSD between 2002 and 2021 were also included. The 28.2% decline in KD cases nationally during 2020 (646 cases) compared with 2018 (894 cases) and 2019 (905 cases) was uneven across the United States. For RCHSD, there was a disproportionate decline in KD cases in 2020 to 2021 compared with the mean (SD) number of cases in earlier years for children aged 1 to 5 years (22 vs 44.9 [9.9]; P = .02), male children (21 vs 47.6 [10.0]; P = .01), and Asian children (4 vs 11.8 [4.4]; P = .046). Mobility data did not suggest that shelter-in-place measures were associated with the number of KD cases. Clinical features including strawberry tongue, enlarged cervical lymph node, and subacute periungual desquamation were decreased during 2020 compared with the baseline period (strawberry tongue: 39% vs 63%; P = .04; enlarged lymph node: 21% vs 32%; P = .09; periungual desquamation: 47% vs 58%; P = .16). School closures, masking mandates, decreased ambient pollution, and decreased circulation of respiratory viruses all overlapped to different extents with the period of decreased KD cases. KD in San Diego rebounded in the spring of 2021, coincident with lifting of mask mandates. Conclusions and Relevance: In this study of epidemiological and clinical features of KD during the COVID-19 pandemic in the United States, KD cases fell and remained low during the period of masking and school closure. Mobility data indicated that differential intensity of sheltering in place was not associated with KD incidence. These findings suggest that social behavior is associated with exposure to the agent(s) that trigger KD and are consistent with a respiratory portal of entry for the agent(s).

Indexed as

COVID-19Mucocutaneous Lymph Node SyndromeChildChild, PreschoolCohort StudiesFemaleFeverHumansMalePandemicsUnited States

Identifiers

PMID35713905
PMCPMC9206189
OpenAlexW4283009387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.